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OBJECTIVES: To classify the characteristics and properties of the pharmacological 
treatments among migraine patients treated by neurologists in Spain. Patients are 
becoming increasingly implicated in treatment decisions. Expectations in relation to 
therapy largely condition satisfaction with the results obtained. METHODS: Multi-
center, cross-sectional study in adult patients with at least one prescription of anti-
migraine drugs within the last year. The protocol was approved by the CREC of La 
Princesa University Hospital (Madrid). Sociodemographic, and clinical characteristics 
of patients, as well as questions regarding their expectations with regard to migraine 
treatments and evaluation of the importance of their attributes are documented. Using 
a treatment expectations questionnaire and applying Kano methodology, sixteen treat-
ment attributes were classiﬁ ed as: Must-be, One-dimensional, Attractive, Indifferent, 
Reverse or Questionable. Patients were required to give informed consent. RESULTS: 
68 neurologists included 174 patients diagnosed with migraine (mean age 39 years; 
75% women). None of the attributes were considered “Must-be”. The attributes 
considered by most patients to be “One-dimensional” were the absence of long-term 
adverse effects (55%), to allow work/study activities (50%), to allow social and family 
relationship (50%), achievement of symptoms relief (47%) and pain relief (44.3%). 
The attributes considered “Attractive” by most patients were: achievement of rapid 
symptoms and pain relief (54%), and achievement of total disappearance of the pain 
(53.4%). The attributes that led to a greater dissatisfaction were the occurrence of 
long-term adverse effects, not to allow work activity or studies and not to achieve 
pain relief. The three attributes that led to a greater satisfaction were achievement of 
total disappearance of the symptoms and the pain, and rapid pain relief. CONCLU-
SIONS: The expectations regarding a medical treatment signiﬁ cantly inﬂ uence the sat-
isfaction reached with the outcome of such treatment. a better knowledge of patient’s 
expectations can lead to a greater satisfaction associated with treatment outcomes.
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MODIFIED LAST OBSERVATION CARRIED FORWARD IS A SUPERIOR 
METHOD OF IMPUTATION
DeGryse R, Lei X, Fainaru I, Turkel C
Allergan, Inc., Irvine, CA, USA
OBJECTIVES: To compare imputation methods using PREEMPT (Phase III REsearch 
Evaluating Migraine Prophylaxis Therapy) clinical data. METHODS: Data were 
analyzed from two phase 3 studies of onabotulinumtoxinA in chronic migraine 
(ICHD-II migraine and ≥15 headache days/month). Each study included a 24-week, 
randomized, double-blind, parallel-group, placebo-controlled phase, followed by a 
32-week, open-label onabotulinumtoxinA treatment phase. The prespeciﬁ ed method 
of imputation of missing data (ie, <20 days of diary data in a 28-day period) was 
modiﬁ ed last observation carried forward (mLOCF), which estimated missing data by 
iteratively multiplying the subject’s most recent count by the subsequent average 
change rate across treatments. We compared mLOCF with last observation carried 
forward (LOCF), baseline observation carried forward (BOCF), mLOCF within-
treatment (mLOCFw), and observed data (without imputation). Simulations to predict 
known data were analyzed using mLOCF, LOCF, and BOCF. RESULTS: 1384 adults 
were randomized (PREEMPT1: onabotulinumtoxinA [n = 341], placebo [n = 338]; 
PREEMPT2: onabotulinumtoxinA [n = 347], placebo [n = 358]). 1026 (74%) of the 
subjects had no missing monthly counts during the double-blind phase (PREEMPT1: 
onabotulinumtoxinA [n = 242], placebo [n = 248]; PREEMPT2: onabotulinumtoxinA 
[n = 258], placebo [n = 278]). Each imputation method (mLOCF, LOCF, BOCF, 
mLOCFw) and observed data generated a similar statistically signiﬁ cant between-
group difference for the primary efﬁ cacy endpoint of headache-day counts at Week 
24 in PREEMPT2 (P < 0.001). Similar results were observed within PREEMPT1 (P < 
0.02). Compared to LOCF and BOCF, mLOCF was superior at predicting known 
values of headache-day counts in simulations that randomly set observed scores to 
missing, as demonstrated by least-squared errors of imputed minus actual counts. 
CONCLUSIONS: PREEMPT treatment differences were similar (and statistically sig-
niﬁ cant) using each imputation method, likely due to low dropout rates within each 
treatment group. Compared to LOCF and BOCF, mLOCF was superior at predicting 
known data. 
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: The incidence rates of atopic dermatitis (AD) and relative risks (RR) 
associated to a brand of partially hydrolyzed 100% whey formula manufactured by 
Nestlé (PHF-W) and to extensively hydrolyzed formulas (EHF-Whey or Casein) were 
reported for the prevention of AD in infants who are not exclusively breastfed. 
METHODS: Szajewska et al. had previously undertaken a meta-analysis determining 
the incidence rates and RRs of PHF-W compared to cow’s milk formula (CMF) and 
EHF but details were not for provided for PHF-W vs. EHF. This analysis sheds light 
on the latter comparisons and extends the analyses to 3-month cycles from birth to 
36-months of age. Included were any relevant randomized controlled trials comparing 
the use of PHF-W with CMF or EHF for the prevention of allergies. The primary 
outcomes of interest were the incidence, cumulative incidence and period prevalence 
of any allergic manifestations and AD in particular. Of 84 retrieved citations, 15 
studies were included for analysis of which 6 studies pertained to PHF-W vs. EHF. 
All efﬁ cacy data were converted into inputs for a spreadsheet decision-analytic eco-
nomic model based on 3-month cycles by applying weights derived from the Szajewska 
et al. meta-analysis and calculating them at 3-month intervals for input into an eco-
nomic model. RESULTS: The analysis sample included 557, 559 and 580 patients for 
PHF-W, EHF-Whey and EHF-Casein, respectively. a RR of 0.75 [0.54,1.05] at 0–12 
months and 0.80 [0.63,1.02] at 0–36 months was obtained for PHF-W vs. EHF-Whey 
while a RR of 1.06 [0.74,1.53] at 0–12 months and 1.13 [0.87,1.47] at 0–36 months 
was determined for PHF-W vs. EHF-Casein. All efﬁ cacy data were adapted into 
3-month indicators. CONCLUSIONS: It appears that the efﬁ cacy of PHF-W falls 
within the range of the other two extensively hydrolyzed formulas. 
SENSORY SYSTEMS DISORDERS – Cost Studies
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USE OF INCREASED DOSAGES OF BIOLOGICS IN PLAQUE PSORIASIS 
AND POTENTIAL SAVINGS BY TREATING HIGH-DOSE PATIENTS WITH 
USTEKINUMAB INSTEAD—A BUDGET IMPACT MODEL
Klesse M, Wolbring F
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OBJECTIVES: Evaluation of real-life dosing of biologics in plaque psoriasis in 
Germany and the potential savings by treating patients with ustekinumab instead of 
using higher doses of TNF-alpha-inhibitors. METHODS: Based on an online survey 
among 100 dermatologists (DocCheck Medical Services, December 2009) the use of 
biologics and their dosing distribution for the treatment of plaque psoriasis was evalu-
ated. The proportion of patients receiving maintenance dosages according to label and 
those receiving a higher dose were evaluated for each biologic separately. a budget 
impact model was created estimating potential savings by treating patients with 
ustekinumab according to label (45 mg in patients ≤100 kg body weight and 90 mg 
in patients >100 kg body weight) instead of high dose TNF-alpha-inhibitors in terms 
of annual medication costs. In this model, costs of the current usage pattern of biolog-
ics were estimated using German pharmacy prices (source: Lauer-Taxe, version June 
1, 2010, most economical pack size). RESULTS: In most cases biologic treatments are 
used according to the respective labels. In some instances, deviating dosages are used: 
14% of adalimumab-treated patients receive an increased dosage of 40 mg every week 
or 80 mg eow, and more than 15% of etanercept-treated patients receive 50 mg twice 
weekly or another deviating dosage as maintenance therapy. 27% of inﬂ iximab-
treated patients receive maintenance injections more frequently than every 8 weeks or 
receive an increased dosage per injection. In Germany, assuming 80% of those high-
dose-TNF-alpha-inhibitor-treated patients are treated with ustekinumab instead, this 
would result in savings of approximately c18 million per year. If induction costs of 
ustekinumab are considered additionally, still c13 million could be saved within one 
year. CONCLUSIONS: Using ustekinumab instead of high dosages of TNF-alpha-
inhibitors for treatment of plaque psoriasis can generate signiﬁ cant savings in medica-
tion costs in Germany.
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OBJECTIVES: Some research has shown that Hand Eczema is often work-related, 
widespread, potentially disabling and costly disease, but misdiagnosed and mistreated. 
Severe Chronic Hand Eczema (CHE) can be particularly burdensome. We aimed to 
assess prevalence, costs and HRQoL in patients with severe CHE. METHODS: A 
naturalistic, multicentre, epidemiologic and cost-of-illness study is being conducted in 
14 Italian dermatological centers. HE patients aged ≥18 years are being enrolled 
through a 6-month period. The following data are being collected: socio-demographic, 
clinical (severity, chronicity and responsiveness to treatment with topical potent cor-
ticosteroids) and, among chronic, severe and refractory patients, data on HRQol 
